Taken together, our research identifies that SAMD4B exerts an oncogenic role in promoting breast cancer progression via activating the Wnt/β-catenin signaling pathway, highlighting its potential as a novel therapeutic target for breast cancer. The gene discussed is SAMD4B; the disease is breast carcinoma.